» Articles » PMID: 36914746

Global Trends in the Epidemiology of Bladder Cancer: Challenges for Public Health and Clinical Practice

Overview
Specialty Oncology
Date 2023 Mar 14
PMID 36914746
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is affected by demographic trends, most notably population growth and ageing, as well as exposure to risk factors, especially tobacco smoking. Consequently, the incidence has not been stable throughout the world over time, nor will it be in the near future. Further primary prevention efforts are of the utmost importance to reduce the medical and financial burden of bladder cancer on populations and health-care systems. Simultaneously, less-invasive and lower-cost approaches for the diagnosis of both primary and recurrent bladder cancers are required to address challenges posed by the increasing shortage of health-care professionals and limited financial resources worldwide. In this regard, urinary biomarkers have demonstrated promising diagnostic accuracy and efficiency. Awareness of the risk factors and symptoms of bladder cancer should also be increased in society, particularly among health-care professionals and high-risk groups. Studies investigating the associations between lifestyle factors and bladder cancer outcomes are scarce and should be a research priority. In this Review, we outline global trends in bladder cancer incidence and mortality, and discuss the main risk factors influencing bladder cancer occurrence and outcomes. We then discuss the implications, challenges and opportunities of these epidemiological trends for public health and clinical practice.

Citing Articles

Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021.

Su X, Tao Y, Chen F, Han X, Xue L Sci Rep. 2025; 15(1):7655.

PMID: 40038504 PMC: 11880295. DOI: 10.1038/s41598-025-92033-5.


Perioperative Intensive Smoking Cessation Intervention Among Smokers Who Underwent Transurethral Resection of Bladder Tumor (TURBT) in Two Different Settings: A Randomized Controlled Trial.

Lydom L, Lauridsen S, Liljendahl M, Schmedes A, Joensen U, Tonnesen H Cancers (Basel). 2025; 17(4).

PMID: 40002306 PMC: 11853449. DOI: 10.3390/cancers17040713.


The Gender-Biased Differential Effect of Mutation on Immune Therapy in Urothelial Carcinoma: A Public Database Study.

Sekino Y, Nakahara H, Ikeda K, Kobatake K, Kohada Y, Tasaka R Cancers (Basel). 2025; 17(3).

PMID: 39941725 PMC: 11816370. DOI: 10.3390/cancers17030356.


Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors.

Scherer T, Dam C, Bieri U, Eberli D, Strebel R Ther Adv Urol. 2025; 17:17562872251315930.

PMID: 39906152 PMC: 11792014. DOI: 10.1177/17562872251315930.


An Unusual Presentation of Bladder Carcinoma in a Visceral Hernia: A Case Report and Literature Review.

Ebrahimi P, Mahdavian A, Mousavinejad M, Ghadimi D, Taheri M, Mahmudi F Cancer Rep (Hoboken). 2025; 8(2):e70128.

PMID: 39894891 PMC: 11788014. DOI: 10.1002/cnr2.70128.


References
1.
Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple K, Paner G . Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol. 2018; 37(1):107-114. DOI: 10.1007/s00345-018-2421-5. View

2.
van Rhijn B, Hentschel A, Brundl J, Comperat E, Hernandez V, Capoun O . Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol. 2021; 4(2):182-191. DOI: 10.1016/j.euo.2020.12.002. View

3.
Cambier S, Sylvester R, Collette L, Gontero P, Brausi M, van Andel G . EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2015; 69(1):60-9. DOI: 10.1016/j.eururo.2015.06.045. View

4.
Oszczudlowski M, Dobruch J . Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer. Transl Androl Urol. 2018; 7(4):749-751. PMC: 6127543. DOI: 10.21037/tau.2018.06.14. View

5.
D Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S . Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. Urol Oncol. 2018; 36(5):239.e1-239.e7. DOI: 10.1016/j.urolonc.2018.01.018. View